ATE124265T1 - Idiotypen-impfung gegen b-zell-lymphoma. - Google Patents

Idiotypen-impfung gegen b-zell-lymphoma.

Info

Publication number
ATE124265T1
ATE124265T1 AT91905685T AT91905685T ATE124265T1 AT E124265 T1 ATE124265 T1 AT E124265T1 AT 91905685 T AT91905685 T AT 91905685T AT 91905685 T AT91905685 T AT 91905685T AT E124265 T1 ATE124265 T1 AT E124265T1
Authority
AT
Austria
Prior art keywords
idiotype
dendritic cells
pulsed
cells
cell lymphoma
Prior art date
Application number
AT91905685T
Other languages
English (en)
Inventor
Heribert Bohlen
Jacques Urbain
Camp Benjamin Van
Kristiaan Thielemans
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23960532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE124265(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Application granted granted Critical
Publication of ATE124265T1 publication Critical patent/ATE124265T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT91905685T 1990-03-14 1991-03-13 Idiotypen-impfung gegen b-zell-lymphoma. ATE124265T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/493,511 US20030072751A1 (en) 1990-03-14 1990-03-14 Idiotypic vaccination against b cell lymphoma

Publications (1)

Publication Number Publication Date
ATE124265T1 true ATE124265T1 (de) 1995-07-15

Family

ID=23960532

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91905685T ATE124265T1 (de) 1990-03-14 1991-03-13 Idiotypen-impfung gegen b-zell-lymphoma.

Country Status (12)

Country Link
US (1) US20030072751A1 (de)
EP (1) EP0521897B1 (de)
JP (1) JP2735947B2 (de)
AT (1) ATE124265T1 (de)
AU (1) AU645552B2 (de)
CA (1) CA2078235C (de)
DE (1) DE69110877T2 (de)
DK (1) DK0521897T3 (de)
ES (1) ES2074268T3 (de)
FI (1) FI105452B (de)
NO (1) NO308509B1 (de)
WO (1) WO1991013632A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
CA2133409C (en) * 1992-04-01 2011-05-24 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
EP1421947A1 (de) * 1992-07-22 2004-05-26 The Trustees Of Princeton University P53 vakzine
DE69331703D1 (de) * 1992-08-21 2002-04-18 Us Gov Health & Human Serv B-lymphomazellinie und antigen
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
WO1997022349A1 (en) * 1995-12-20 1997-06-26 The Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
CA2321093A1 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
CA2368855C (en) 1999-04-20 2012-05-29 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Also Published As

Publication number Publication date
JPH05507905A (ja) 1993-11-11
CA2078235A1 (en) 1991-09-15
EP0521897B1 (de) 1995-06-28
AU7488691A (en) 1991-10-10
ES2074268T3 (es) 1995-09-01
FI924082A (fi) 1992-09-11
DE69110877D1 (de) 1995-08-03
EP0521897A1 (de) 1993-01-13
CA2078235C (en) 2004-01-20
JP2735947B2 (ja) 1998-04-02
FI924082A0 (fi) 1992-09-11
US20030072751A1 (en) 2003-04-17
NO923542D0 (no) 1992-09-11
AU645552B2 (en) 1994-01-20
DE69110877T2 (de) 1995-11-16
NO923542L (no) 1992-09-11
NO308509B1 (no) 2000-09-25
WO1991013632A1 (en) 1991-09-19
FI105452B (fi) 2000-08-31
DK0521897T3 (da) 1995-11-13

Similar Documents

Publication Publication Date Title
DE69110877D1 (de) Idiotypen-impfung gegen b-zell-lymphoma.
DK0669836T3 (da) Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
DK0504177T3 (da) IL-11, et pattedyrcytokin
DE69418699D1 (de) Induktion der antworten zytotoxischer t-lymphozyten
FR2620941B1 (fr) Vaccin contenant des adjuvants et des antigenes tumoraux
ZA938466B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentation antigen for treatment of B cell lymphoma
DE68924162D1 (de) Stressproteine und verwendungen dafür.
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
DE69031120D1 (de) Her2 extrazellulare domäne
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
FI913275A (fi) Foerfarande foer foerbaettring av sjukdomsmottstaondskraft.
ATE231184T1 (de) Impfstoffe gegen die pest
IT8648096A0 (it) Procedimento per l'iniezione di carburante nei motori a due tempi e dispositivo per la realizzazione del procedimento
ES8608883A1 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
KR890700659A (ko) 항원-특이적 t세포주의 생성방법 및 이의 치료적 용도
PT1021196E (pt) Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio
IT8024091A0 (it) Dispositivo di comando per determinare l'istante di accensione e dosare il carburante per un motore endotermico.
IT8050422A0 (it) Dispositivo per la riduzione delle vibrazioni di motori in particolare di motori endotermici ad iniezione
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
GR3021983T3 (en) Cross-reactive influenza a immunization
Baenkler Autoimmunity in infectious diseases.
IT1229943B (it) Procedimento e dispositivo di misura dell'anticipo di inizio mandata dell'iniezione, particolarmente in motori diesel
UA11418A1 (uk) Пристрій для введеhhя лікарських препаратів твариhам hа відстаhі
SU681928A1 (ru) Адъювант
IT1181513B (it) Sistema di fissaggio dell'imbottitura sui fianchi di una poltrona

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee